Drug intelligence / Profile preview

chlorphenamine + phenylephrine + paracetamol

Development stage
Unknown
Lead developer
Biofarma
Modality
Small Molecules
Administration
Oral
01

Overview

Gerakon Forte is a branded generic oral combination medication developed and marketed by Biofarma for the symptomatic relief of common cold, flu, and upper respiratory tract infections. It is formulated as an immediate-release tablet containing three active ingredients: paracetamol (650 mg), an analgesic and antipyretic that reduces pain and fever; phenylephrine hydrochloride (10 mg), a decongestant that relieves nasal stuffiness by constricting blood vessels; and chlorpheniramine maleate (4 mg), a first-generation antihistamine that alleviates allergic symptoms such as runny nose, sneezing, and watery eyes. Together, these components target multiple pathways to manage the systemic and localized symptoms of respiratory illnesses.

Brand names
Gerakon FortGerakon Forte
Other names
acetaminophen + chlorphenamine + phenylephrineacetaminophen + chlorpheniramine + phenylephrinechlorphenamine + phenylephrine + paracetamolchlorphenamine maleate + phenylephrine hydrochloride + paracetamolchlorpheniramine + phenylephrine + paracetamolchlorpheniramine maleate + phenylephrine hydrochloride + paracetamol
02

Targets

ADRA1A (α1A)SERT (Sodium-dependent serotonin transporter)COXHRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on chlorphenamine + phenylephrine + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorphenamine + phenylephrine + paracetamol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call